BIM
SAGE

Bogle Investment Management’s Sage Therapeutics SAGE Stock Holding History

Bogle Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-80,311
Closed -$3.34M – 304
2020
Q2 		$3.34M Buy
+80,311
New +$2.91M 0.56% 82

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bogle Investment Management's SAGE Position: Q3 2020 in Review

Bogle Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2020, closing a stake of 80,311 shares — an estimated $3.34M sold.

Bogle Investment Management first reported a position in SAGE in Q2 2020 and held it in 1 quarter. The position peaked at $3.34M in Q2 2020. 231 funds tracked by Wall St. Rank hold SAGE as of Q3 2020.

  • Bogle Investment Management reported no remaining Sage Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Bogle Investment Management sold 80,311 Sage Therapeutics shares in Q3 2020, an estimated $3.34M.
  • Bogle Investment Management first reported a position in Sage Therapeutics in Q2 2020 and held it in 1 quarter.
  • Bogle Investment Management's Sage Therapeutics position peaked at $3.34M in Q2 2020.
  • 231 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.